Abstract:Leigh Ramos-Platt, 1 Lauren Elman, 2 Perry B Shieh 3 1 Department of Pediatrics, Keck School of Medicine, University of Southern California and Children's Hospital of Los Angeles, Los Angeles, CA, USA; 2 Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; 3 Department of Neurology and Pediatrics, University of California Los Angeles, Los Angeles, CA, USA Correspondence: Perry B Shieh, Department of Neurology and Pediatrics, University of California Los Angeles, Los Angeles, CA, USA, Email Spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disorder that, until recently, was the most common inherited cause of infant mortality. Since 2016, three disease-modifying therapies have emerged, nusinersen, onasemnogene abeparvovec-xioi, and risdiplam, leading to a transformation in the SMA treatment landscape, changes in disease trajectories, and a profound impact on clinical care. This environment poses a challenge to making informed treatment decisions, including initial treatment choice, treatment changes, and potential use of combination therapies as new data emerge. To better understand factors that influence physician-patient decision-making, a roundtable discussion was convened by Biogen (sponsor) with a panel of four US SMA experts. This report shares the panel's opinions and clinical experiences, with the goals of helping clinicians and people with SMA and their families to better understand the factors influencing real-world treatment decisions and stimulating a broader discussion in the SMA community. The panelists highlighted that patients are often heavily involved in treatment decisions, and physicians must be aware of current data to guide patients in making the best decisions. Thus, in the absence of data from head-to-head treatment comparisons, physicians' roles include reviewing treatment options and describing what is known of the benefits, challenges, and potential side effects of each therapy with patients and families. For infants and young children, the panelists expressed a sense of urgency for early intervention to minimize motor function loss, whereas the goal for adults is long-term disease stabilization. In the panelists' experience, factors that influence patients' decisions to change to an alternative therapy include convenience, administration route, novelty of therapy, and hope for improved function, while reasons for returning to a previous therapy include a perception of decreased efficacy and side effects. Ongoing clinical trials and analyses of real-world experiences should further inform treatment decisions and optimize patient outcomes. Graphical Keywords: nusinersen, onasemnogene abeparvovec-xioi, risdiplam, spinal muscular atrophy Graphical People with spinal muscular atrophy (SMA), a rare disease caused by a change in the survival motor neuron 1 gene, do not make enough SMN protein to maintain motor neurons, nerve cells that control muscle function. This results in muscle weakness that worsens over time. Nusinersen, onasemnogene abeparvovec-xioi, and risdiplam are drugs that increase SMN protein. Nusinersen is injected into a space in the lower back (lumbar region) below the end of the spinal cord every 4 months. Onasemnogene abeparvovec-xioi, a gene replacement therapy, is injected once into a vein. Risdiplam is taken by mouth daily. Biogen, the manufacturer of nusinersen, organized a meeting with four SMA doctors to discuss their experiences with SMA treatments and how patients choose a drug. In the experts' opinions: Since December 2016, the treatment landscape in spinal muscular atrophy (SMA) has gone through a transformative evolution, with the advancement and approval of multiple disease-modifying treatment options. 1–4 Clinicians, patients, and caregivers now face more complex considerations when evaluating opportunities to individualize treatment decisions that address the unique interests and needs of each patient. 5–7 SMA is a rare, progressive neuromuscular disorder characterized by muscle weakness and atrophy resulting from irreversible degeneration of the anterior horn motor neurons in the spinal cord and the brain stem nuclei. 8,9 SMA occurs in approximately one per 10,000 live births. 9 Until this decade, SMA was the most common inherited cause of infant mortality. 10 In about 95–98% of patients with SMA, the disease is caused by a deletion in both alleles of the survival motor neuron 1 gene ( SMN1 ) on chromosome 5q; in the remainder, small mutations in SMN1 have been identified. 9 In either case, the deletions/mutations lead to reduced SMN protein levels, which results in the degeneration of motor neurons. 8,9 Individuals with S -Abstract Truncated-

Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction

Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

FIREFISH Part 2: 24-Month Efficacy and Safety of Risdiplam in Infants with Type 1 Spinal Muscular Atrophy (SMA)

Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis

FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA)

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs

FIREFISH Parts 1 and 2: 24-Month Safety and Efficacy of Risdiplam in Type 1 SMA (S39.005)

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1

A Croatian Real-World Experience on Effectiveness and Safety

FIREFISH Part 2: 24-Month Efficacy and Safety of Risdiplam in Infants with Type 1 Spinal Muscular Atrophy (SMA) (4126)

An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments

Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy

RAINBOWFISH: A Study of Risdiplam in Newborns with Presymptomatic Spinal Muscular Atrophy (SMA) (4281)

Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians

Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy

P.362RAINBOWFISH: A Study of Risdiplam (RG7916) in Newborns with Pre-Symptomatic Spinal Muscular Atrophy (SMA)

Analysis of blood concentrations and clinical application of risdiplam in patients with spinal muscular atrophy using ultra-high performance liquid chromatography-tandem mass spectrometry